ArticleFundamental research2026
Harmine ameliorates steroid-induced osteonecrosis of the femoral head by modulating metabolism and ferroptosis via HIF1-α.
Article in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Steroid-induced osteonecrosis of the femoral head (SONFH) often leads to disability in the terminal stage, and there are still no effective drugs for prevention. Harmine (Hm), which is extracted from Peganum harmala L., is a β-carboline alkaloid with a number of biological and pharmacological properties. In this study, we discovered the protective effect of Hm on SONFH in rats. In vitro studies showed that Hm could ameliorate oxidative stress and facilitate osteogenic differentiation in bone mesenchymal stem cells (BMSCs), which play an important role in bone development and repair. Bioinformatics analysis revealed that ferroptosis and the HIF1-α pathway played an important role in SONFH pathogenesis. Mechanistically, Hm treatment alleviated ferroptosis by promoting HIF1-α expression in BMSCs. When shHif1a was used to inhibit HIF1-α expression, the protective effects of Hm disappeared. Meanwhile, we further found that Hm intervention promoted HIF1-α expression to increase GSH production and the GSH/GSSG ratio, which further promoted the scavenging of free radicals. In summary, Hm may be a promising candidate for the treatment of SONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.